Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Jetstar to Charge for Overhead Cabin Bags From February 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
NEW YORK, March 14, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Synergy Pharmaceuticals Inc. ("Synergy") (NASDAQ:SGYP) between November 10, 2016 and November 14, 2017. You are hereby notified that securities class action lawsuits have been commenced in the USDC for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra-d/synergy-pharmaceuticals-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaints allege that throughout the class periods Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the loan from CRG Partners III L.P. (“CRG Loan”) did not fund Synergy’s operations through 2019; (2) the Company could not access the second tranche of $100 million financing on or before February 28, 2018 without issuing dilutive equity; and (3) the Company could not access the third tranche of the CRG Loan if and when needed because terms were required to be met in order to access those tranches.
If you suffered a loss in Synergy you have until April 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
